Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT for the Treatment of Schizophrenia in Adolescents
NCT07288567Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Bristol Myers Squibb. Started Jan 2026; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07288567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288567.